Health Economics Assessment of Rilpivirine Versus Comparators as First-Line Antiretroviral Therapies in HIV-1 Patients with a Viral Load (VL) ≤100,000 Copies/mL in France
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.216
https://www.valueinhealthjournal.com/article/S1098-3015(13)02121-9/fulltext
Title :
Health Economics Assessment of Rilpivirine Versus Comparators as First-Line Antiretroviral Therapies in HIV-1 Patients with a Viral Load (VL) ≤100,000 Copies/mL in France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02121-9&doi=10.1016/j.jval.2013.08.216
First page :
A359
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
203